Identification of small molecules that inhibit GSK-3β through virtual screening

Glycogen synthase kinase-3β (GSK-3β) is involved in glycogen metabolism, neuronal cell development, osteoblast differentiation. Small molecule inhibitors of GSK-3β have various therapeutic potential for the treatment of diabetes type II, bipolar disorders, stroke and chronic inflammatory disease. To identify GSK-3β inhibitors with novel scaffold from chemical library, we primarily screened out putative inhibitors through computer modeling and subsequently evaluated the inhibitory activity of selected compounds against GSK-3β by in vitro Z’-LYTE™ assay. A series of compound KRMs strongly inhibited phosphorylation of its substrate with IC50 value of approximately 0.5 μM. Also, we demonstrated that KRM-189 and KRM-191 competed with ATP for GSK-3β, leading to decreased Vmax and constant Km with increasing concentrations of ATP as determined from Lineweaver–Berk equation. Moreover, they showed the selectivity for GSK-3β over other kinases with IC50 values of 2 to 10 μM or more Incubation of cells with KRM-191 with highly selective and potent inhibitory activity caused accumulation of β-catenin, downstream of GSK-3β signaling pathway, indicating that small molecule can prevent degradation of β-catenin via GSK-3β inhibition. Our results suggest that modeling in combination with in vitro assays can be used for the identification of selective and potent inhibitors.